{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:57:37Z","timestamp":1791262657168,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100020624","name":"NIHR Nottingham Biomedical Research Centre","doi-asserted-by":"publisher","award":["IS\u2010BRC\u20101215\u201020003"],"award-info":[{"award-number":["IS\u2010BRC\u20101215\u201020003"]}],"id":[{"id":"10.13039\/501100020624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/Z505183\/1"],"award-info":[{"award-number":["MR\/Z505183\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>T\u2010cell\u2013engaging bispecific antibodies are increasingly utilised in haematological malignancies and are beginning to be adopted in solid\u2010tumour treatment protocols. Cytokine release syndrome and neurotoxicity are well recognised, but target\u2010specific dermatological adverse event reporting patterns remain poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 12,333,305 deduplicated FAERS reports from 2016Q1 to 2026Q1, including 23,386 reports exposed to ten T\u2010cell\u2013engaging bispecific antibodies grouped by target: CD19, CD20, BCMA, GPRC5D and DLL3. A disease\u2010matched haematologic\u2010oncology comparator cohort contained 1,062,195 reports. Canada Vigilance provided a secondary directional comparison using 755,911 reports from 2016Q1 to 2025Q4 including 662 unique exposed reports. Outcomes were any cutaneous adverse event, broad severe cutaneous adverse reaction, and narrow Stevens\u2010Johnson syndrome\/toxic epidermal necrolysis. Multivariable models adjusted for age, sex, cancer indication, polypharmacy and classical culprit drugs. Cox models assessed target\u2010specific timing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among exposed FAERS reports, 1394 (5.96%) included any cutaneous adverse event, 61 (0.26%) broad severe cutaneous adverse reaction and 9 (0.04%) narrow Stevens\u2010Johnson syndrome\/toxic epidermal necrolysis. After disease matching, no clear class\u2010level excess of severe cutaneous reaction reporting was observed. Talquetamab had the highest cutaneous reporting proportion (471\/1822; 25.8%) and an elevated timing estimate (hazard ratio 1.34; 95% CI, 1.06\u20131.69), with enrichment for skin, hair, sweat\u2010gland and rash phenotypes. Tarlatamab showed an exploratory early\u2010onset pattern (hazard ratio 3.36; 95% CI, 1.68\u20136.72; median onset, 4\u2009days), based on only eight reports with usable latency data. Canada Vigilance showed a similar direction of reporting for GPRC5D\/any cutaneous adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>T\u2010cell\u2013engaging bispecific antibodies did not show clear class\u2010level excess in severe cutaneous adverse\u2010event reporting after disease matching. Talquetamab showed higher reporting of skin changes, hyperhidrosis, hair abnormalities and rash, whereas tarlatamab showed a possible early\u2010onset cutaneous reporting pattern based on a small number of reports with usable timing data. These findings support target\u2010 and timing\u2010aware dermatological monitoring and require prospective confirmation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.72241","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:38:31Z","timestamp":1788158311000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Target\u2010Specific Dermatological Adverse Event Reporting With T\u2010Cell\u2013Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of\n                    <scp>FAERS<\/scp>\n                    and Canada Vigilance, 2016\u20132026"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-5295","authenticated-orcid":false,"given":"Saikat","family":"Mandal","sequence":"first","affiliation":[{"name":"Translational Medical Sciences, School of Medicine University of Nottingham  Nottingham UK"},{"name":"NIHR Nottingham Biomedical Research Centre Nottingham University Hospitals NHS Trust  Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-5158","authenticated-orcid":false,"given":"Manideepa","family":"Maji","sequence":"additional","affiliation":[{"name":"Hull York Medical School University of Hull  Hull UK"},{"name":"Haematology Hull University Teaching Hospitals NHS Trust  Hull UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-2569","authenticated-orcid":false,"given":"Arkadeep","family":"Dhali","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Trust  Sheffield UK"},{"name":"School of Medicine, Dentistry and Biomedical Sciences Queen's University Belfast  Belfast UK"},{"name":"Faculty of Health Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201000989\u2010w"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_11_7_1","unstructured":"European Medicines Agency (EMA) \u201cTalvey (Talquetamab) | European Medicines Agency (EMA) [Internet] \u201d (2025) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/talvey."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980"},{"key":"e_1_2_11_9_1","volume-title":"IMDELLTRA (Tarlatamab\u2010Dlle) Prescribing Information","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2025.09.001"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010024\u201001421\u20109"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.06.024"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33765"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.4349"},{"key":"e_1_2_11_14_2","doi-asserted-by":"crossref","unstructured":"Erratum in:JAMA Oncology11 no. 12 (2025): 1555 https:\/\/doi.org\/10.1001\/jamaoncol.2025.5748.","DOI":"10.1001\/jamaoncol.2025.5748"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022\u2010202X.2004.12628.x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10030420"},{"key":"e_1_2_11_18_1","unstructured":"U.S. Food and Drug Administration \u201cFDA Adverse Event Reporting System (FAERS) Database \u201d accessed May 11 2026 https:\/\/www.fda.gov\/drugs\/drug\u2010approvals\u2010and\u2010databases\/fda\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers\u2010database."},{"key":"e_1_2_11_19_1","unstructured":"Health Canada \u201cCanada Vigilance Adverse Reaction Online Database \u201d accessed May 11 2026 https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/drugs\u2010health\u2010products\/medeffect\u2010canada\/adverse\u2010reaction\u2010database.html."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18132128"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyr218"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648\u2010199209000\u201000012"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2221756"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.003"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72241","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:49:00Z","timestamp":1791262140000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/cam4.72241"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72241","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]},"assertion":[{"value":"2026-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72241"}}